Common use of Material Adverse Changes Clause in Contracts

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 208 contracts

Sources: Open Market Sale Agreement (Black Diamond Therapeutics, Inc.), Sales Agreement (UroGen Pharma Ltd.), Open Market Sale Agreement (Iovance Biotherapeutics, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 15 contracts

Sources: Sales Agreement (MICROSTRATEGY Inc), Sales Agreement (MICROSTRATEGY Inc), Sales Agreement (MICROSTRATEGY Inc)

Material Adverse Changes. Except as disclosed in the Registration Statement, the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 14 contracts

Sources: Sales Agreement (Solid Biosciences Inc.), Sales Agreement (Solid Biosciences Inc.), Open Market Sale Agreement (Scholar Rock Holding Corp)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 14 contracts

Sources: Open Market Sale Agreement (Kyverna Therapeutics, Inc.), Open Market Sale Agreement (Boundless Bio, Inc.), Sales Agreement (Innate Pharma SA)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given received by the Company of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 10 contracts

Sources: Open Market Sale Agreement (Arrowhead Pharmaceuticals, Inc.), Open Market Sale Agreement (Arrowhead Pharmaceuticals, Inc.), Open Market Sale Agreement (Eledon Pharmaceuticals, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 7 contracts

Sources: Open Market Sale Agreement (AC Immune SA), Open Market Sale Agreement (Spruce Biosciences, Inc.), Open Market Sale Agreement (AC Immune SA)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the reasonable judgment of the Agent there nothing shall not have occurred any that would reasonably be expected to have a Material Adverse ChangeEffect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 6 contracts

Sources: Open Market Sale Agreement (Intellia Therapeutics, Inc.), Open Market Sale Agreement (CRISPR Therapeutics AG), Open Market Sale Agreement (Intellia Therapeutics, Inc.)

Material Adverse Changes. Except as disclosed in the Registration Statement or Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 6 contracts

Sources: Open Market Sale Agreement (Aldeyra Therapeutics, Inc.), Open Market Sale Agreement (Aldeyra Therapeutics, Inc.), Open Market Sale Agreement (OptiNose, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (bB) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 4 contracts

Sources: Open Market Sale Agreement (Jasper Therapeutics, Inc.), Open Market Sale Agreement (NeuBase Therapeutics, Inc.), Open Market Sale Agreement (Viridian Therapeutics, Inc.\DE)

Material Adverse Changes. Except as disclosed in the Registration Statement, Prospectus and the Time of Sale Information, (a) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 4 contracts

Sources: Equity Distribution Agreement (BridgeBio Pharma, Inc.), Open Market Sale Agreement (CureVac N.V.), Open Market Sale Agreement (BridgeBio Pharma, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus U.S. Prospectuses and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 4 contracts

Sources: Open Market Sale Agreement (BELLUS Health Inc.), Open Market Sale Agreement (Neptune Wellness Solutions Inc.), Open Market Sale Agreement (Aurinia Pharmaceuticals Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale InformationProspectus, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 4 contracts

Sources: Sales Agreement (Orchestra BioMed Holdings, Inc.), Open Market Sale Agreement (HOOKIPA Pharma Inc.), Open Market Sale Agreement (Orchestra BioMed Holdings, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, : (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 3 contracts

Sources: At the Market Issuance Sales Agreement (374Water Inc.), At the Market Issuance Sales Agreement (374Water Inc.), Open Market Sale Agreement (374Water Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 3 contracts

Sources: Sales Agreement (Inventiva S.A.), Sales Agreement (Inventiva S.A.), Sales Agreement (Inventiva S.A.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any "nationally recognized statistical rating organization" as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 3 contracts

Sources: Sales Agreement (MindWalk Holdings Corp.), Sales Agreement (ImmunoPrecise Antibodies Ltd.), Open Market Sale Agreement (ImmunoPrecise Antibodies Ltd.)

Material Adverse Changes. Except as disclosed in the Registration Statement, Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 3 contracts

Sources: Sales Agreement (Cibus, Inc.), Open Market Sale Agreement (Calyxt, Inc.), Open Market Sale Agreement (LogicBio Therapeutics, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Changematerial adverse change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 3 contracts

Sources: Open Market Sale Agreement (ADC Therapeutics SA), Open Market Sale Agreement (Aura Biosciences, Inc.), Open Market Sale Agreement (ADC Therapeutics SA)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent Forward Purchaser there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Open Market Sale Agreement (Janus International Group, Inc.), Open Market Sale Agreement (Smart Sand, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus Registration Statement and the Time of Sale InformationProspectus, (a) in the judgment of the Agent Agent, there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Equity Distribution Agreement (Lithium Americas Corp.), Equity Distribution Agreement (Lithium Americas Corp.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (bB) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Open Market Sale Agreement (Corbus Pharmaceuticals Holdings, Inc.), Open Market Sale Agreement (Corbus Pharmaceuticals Holdings, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries Subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Open Market Sale Agreement (Vuzix Corp), Open Market Sale Agreement (Tyme Technologies, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries Subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Equity Distribution Agreement (Tilray Brands, Inc.), Sales Agreement (Tilray Brands, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the reasonable judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Open Market Sale Agreement (Vapotherm Inc), Open Market Sale Agreement (scPharmaceuticals Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any public notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 2 contracts

Sources: Open Market Sale Agreement (ImmunoGen, Inc.), Open Market Sale Agreement (ImmunoGen, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given by the Company of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries the Subsidiary by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Milestone Pharmaceuticals Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, Information (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Postal Realty Trust, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus Prospectuses and the Time of Sale Information, (a) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its the subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange ActAct that has been retained by the Company.

Appears in 1 contract

Sources: Equity Distribution Agreement (Nouveau Monde Graphite Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries Subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (VectivBio Holding AG)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Designated Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Berry Corp (Bry))

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Representation Date Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (ASLAN Pharmaceuticals LTD)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, Information (a) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.. 276938411 v5

Appears in 1 contract

Sources: Open Market Sale Agreement (Postal Realty Trust, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus Prospectuses and the Time of Sale Information, (a) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries the Subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange ActAct that has been retained by the Company.

Appears in 1 contract

Sources: Equity Distribution Agreement (Aphria Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (bB) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries Subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Fluidigm Corp)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, any Free Writing Prospectus: (aA) in the reasonable judgment of the Agent Agent, there shall not have occurred any Material Adverse Change; and (bB) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Athersys, Inc / New)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent Agents, there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any "nationally recognized statistical rating organization" as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Lithium Americas Corp.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries subsidiary by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Constellation Pharmaceuticals Inc)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries the Subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (NantHealth, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (bB) there shall not have occurred any downgrading, nor and no written notice shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Fuelcell Energy Inc)

Material Adverse Changes. Except as disclosed in the Prospectus Registration Statement and the Time of Sale InformationProspectuses, (a) in the judgment of the Agent Agents, there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Equity Distribution Agreement (Lithium Americas Corp.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of under Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Contango Oil & Gas Co)

Material Adverse Changes. Except as disclosed in the applicable Prospectus and the applicable Time of Sale Information, (a) in the judgment of the Agent Agents there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Omnibus Sales Agreement (Strategy Inc)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse ChangeEffect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Vaxcyte, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (bB) there shall not have occurred any downgrading, nor and no written notice shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Fuelcell Energy Inc)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the reasonable judgment of the Agent there shall not have occurred any Material Adverse Change; and (bB) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Carrols Restaurant Group, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Changematerial adverse effect; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Third Harmonic Bio, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (aA) in the reasonable judgment of the Agent Forward Purchaser there shall not have occurred any Material Adverse Change; and (bB) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Carrols Restaurant Group, Inc.)

Material Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given received by the Company of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries the Subsidiary by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Milestone Pharmaceuticals Inc.)

Material Adverse Changes. Except as disclosed in the Registration Statement or the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.

Appears in 1 contract

Sources: Open Market Sale Agreement (Capital Clean Energy Carriers Corp.)